LabConnect Elevates Bill Finger to Senior Vice President of Global Strategic Services
LabConnect has made significant strides in enhancing its leadership by appointing Bill Finger as the Senior Vice President of Global Strategic Services. This appointment is effective from September 10, 2025, marking a pivotal moment in the company's strategic direction.
With over 25 years of experience in diagnostics and clinical research, Bill is well-equipped to lead LabConnect’s initiatives. He possesses a deep understanding of the pharmaceutical and laboratory landscapes worldwide. His background includes notable roles such as the Vice President and General Manager for Pharmaceutical Services at Quest Diagnostics, and he has served as the Chief Operating Officer for Interpace Pharma Solutions. These roles have solidified his reputation as an innovative thinker capable of developing strategies that drive organizational performance while focusing on operational excellence.
In his new role at LabConnect, Bill Finger will oversee several critical teams responsible for scientific services, consulting, data management, and functional service provider (FSP) offerings. His leadership is anticipated to promote innovation and present tailored solutions that meet the needs of labs and pharmaceutical companies globally.
Wes Wheeler, CEO of LabConnect, expressed confidence in Bill’s leadership, noting, “Bill's extensive expertise in diagnostics and clinical research represents a tremendous asset for LabConnect. His experience positions us to continue anticipating the needs of our clients and providing innovative solutions.” This statement underscores the strategic emphasis that LabConnect is placing on operational excellence and client-focused service delivery.
LabConnect has positioned itself as a leading provider of central laboratory services, FSP, and scientific consulting. The company specializes in managing analytically and logistically complex studies, including areas like immuno-oncology, cell and gene therapies, as well as rare and orphan diseases. By leveraging state-of-the-art technology and world-class labs, LabConnect facilitates a seamless integration of services which sets it apart in the marketplace.
Clients benefit from LabConnect’s easy access to both existing and emerging markets, expanding their opportunities for drug development and facilitating comprehensive analytical support.
As LabConnect moves forward, the addition of Bill Finger is expected to accelerate its growth trajectory and enhance client interaction across multiple sectors, positioning the company as a robust partner in drug development. Investors and stakeholders alike are encouraged to follow LabConnect’s developments as it unveils further initiatives following this leadership change.
To learn more about LabConnect and its services, please visit www.LabConnect.com. Additionally, stay updated by following their LinkedIn page to gain insights into their latest advancements and offerings in the field.
With over 25 years of experience in diagnostics and clinical research, Bill is well-equipped to lead LabConnect’s initiatives. He possesses a deep understanding of the pharmaceutical and laboratory landscapes worldwide. His background includes notable roles such as the Vice President and General Manager for Pharmaceutical Services at Quest Diagnostics, and he has served as the Chief Operating Officer for Interpace Pharma Solutions. These roles have solidified his reputation as an innovative thinker capable of developing strategies that drive organizational performance while focusing on operational excellence.
In his new role at LabConnect, Bill Finger will oversee several critical teams responsible for scientific services, consulting, data management, and functional service provider (FSP) offerings. His leadership is anticipated to promote innovation and present tailored solutions that meet the needs of labs and pharmaceutical companies globally.
Wes Wheeler, CEO of LabConnect, expressed confidence in Bill’s leadership, noting, “Bill's extensive expertise in diagnostics and clinical research represents a tremendous asset for LabConnect. His experience positions us to continue anticipating the needs of our clients and providing innovative solutions.” This statement underscores the strategic emphasis that LabConnect is placing on operational excellence and client-focused service delivery.
LabConnect has positioned itself as a leading provider of central laboratory services, FSP, and scientific consulting. The company specializes in managing analytically and logistically complex studies, including areas like immuno-oncology, cell and gene therapies, as well as rare and orphan diseases. By leveraging state-of-the-art technology and world-class labs, LabConnect facilitates a seamless integration of services which sets it apart in the marketplace.
Clients benefit from LabConnect’s easy access to both existing and emerging markets, expanding their opportunities for drug development and facilitating comprehensive analytical support.
As LabConnect moves forward, the addition of Bill Finger is expected to accelerate its growth trajectory and enhance client interaction across multiple sectors, positioning the company as a robust partner in drug development. Investors and stakeholders alike are encouraged to follow LabConnect’s developments as it unveils further initiatives following this leadership change.
To learn more about LabConnect and its services, please visit www.LabConnect.com. Additionally, stay updated by following their LinkedIn page to gain insights into their latest advancements and offerings in the field.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.